{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:09:49Z","timestamp":1781021389803,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.3816\/cgc.2007.n.003","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:11:28Z","timestamp":1221081088000},"page":"271-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy"],"prefix":"10.3816","volume":"5","author":[{"given":"Ron S.","family":"Israeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Saltzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diep N.H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam M.","family":"Warsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo V.","family":"Lacerna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2007.n.003_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.3816\/CGC.2007.n.003_bib2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CGC.2007.n.003_bib3","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CGC.2007.n.003_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CGC.2007.n.003_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2007.n.003_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropinreleasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"10.3816\/CGC.2007.n.003_bib7","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol"},{"key":"10.3816\/CGC.2007.n.003_bib8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1359\/JBMR.050520","article-title":"Identification of high-risk individuals for hip fracture: a 14-year prospective study","volume":"20","author":"Nguyen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CGC.2007.n.003_bib9","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-naive men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CGC.2007.n.003_bib10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2007.n.003_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CGC.2007.n.003_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.3816\/CGC.2007.n.003_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2007.n.003_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drugs Aging"},{"key":"10.3816\/CGC.2007.n.003_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","article-title":"Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy","volume":"67","author":"Bruder","year":"2006","journal-title":"Urology"},{"key":"10.3816\/CGC.2007.n.003_bib16","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2007.n.003_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cncr.21381","article-title":"Changes in bone mineral density and body composition during Initials and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CGC.2007.n.003_bib18","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2007.n.003_bib19","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2007.n.003_bib20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/jbmr.5650091002","article-title":"Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results","volume":"9","author":"Genant","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CGC.2007.n.003_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2007.n.003_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2007.n.003_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CGC.2007.n.003_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.3816\/CGC.2007.n.003_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits cancer adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2007.n.003_bib27","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2007.n.003_bib28","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2007.n.003_bib29","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2007.n.003_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate therapy","volume":"63","author":"Gertz","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.3816\/CGC.2007.n.003_bib31","series-title":"Zometa [package insert]","year":"2005"},{"key":"10.3816\/CGC.2007.n.003_bib32","doi-asserted-by":"crossref","unstructured":"Michaelson MD, Lee H, Kaufman DS, et al. Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized placebo-controlled trial. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA. Abstract #4515.","DOI":"10.1200\/jco.2006.24.18_suppl.4515"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:59Z","timestamp":1761564059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311700878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1558767311700878"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2007.n.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2007.n.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}